Guardian Technology Partners, LLC Receives 1st Automated Tuberculosis Detection System Order From South Africa

HERNDON, VA--(Marketwire - April 20, 2010) -

Guardian Technologies International, Inc. (OTCBB: GDTI) has received its first order for three fully automated Signature Mapping Tuberculosis Diagnostic (TBDx™) systems for planned shipment at the end of April. The order is in preparation for the final clinical evaluation of the TBDx fully automated detection system that will begin in May 2010.

“Guardian Technologies is extremely proud to deliver to the South African National Health Laboratory Services (“NHLS”) the first total tuberculosis diagnostic solution that addresses the dual challenges of detection and slide throughput,” states Rich Borrelli, Guardian’s Vice President of Healthcare. “Testing of the automated TBDx system to date indicates that it provides a fast, accurate diagnosis at a low cost without requiring clean rooms, cultures or other resource intensive processes. Successful completion of the final clinical evaluation in South Africa will set the stage for the introduction of the fully automated system to other countries faced with large, growing volumes of TB such as India, China, and Russia.”

The breakthrough TBDx system combines automated digital image analysis software to detect TB in sputum microscopy samples using a fully automated slide handling system capable of continuously processing 200 slides without the need for human intervention. The complete automated system will provide the NHLS with the ability to eliminate tedious and time-consuming diagnostic efforts while more consistently and accurately detecting tuberculosis bacilli and maintaining a low false positive rate.

The final clinical evaluation has two objectives: (i) confirm the initial clinical results obtained in October 2009 utilizing the auto-focus integrated microscope and camera capability, and (ii) measure the operational efficiencies and potential cost-savings of fully automated operations. The measurement of slide analysis throughput is required for NHLS to determine the quantity of required systems and deployment strategy. Post-clinical evaluation, the three TBDx systems will be transitioned to NHLS laboratories most heavily involved in ongoing tuberculosis research.

About Guardian Technologies International:
Guardian Technologies uses high-performance imaging technologies and advanced analytics to create integrated information management products and services. Currently, the company offers products and services for use in disease detection and airport security. By automating the processing of large quantities of graphic, numeric, and textual data, Guardian allows organizations to more efficiently detect, extract, analyze or effectively act upon the information. Guardian’s solutions are designed to improve the quality and speed of decision-making and enhance organizational productivity and accuracy. Founded in 2003, Guardian is publicly traded on Nasdaq as GDTI.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995:
Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the markets, variations in the company’s cash flow, competition, celebrity programs, business development efforts, technology availability and cost of materials and other risk factors. Factors that could cause actual results to differ materially are discussed in the Company’s most recent filings with the Securities and Exchange Commission.